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Background: Neuromuscular impairment makes individuals with cerebral palsy (CP) more prone to drooling. 
Among the treatment options, there are procedures that interfere with saliva production. It is imperative to evalu-
ate the effect of the different modalities since the reduction in salivary flow rate/production may exacerbate the 
risk of dental caries.
Material and Methods: The aim of this study was to compare the effects of different treatments for drooling on 
caries risk and salivary parameters in children and adolescents with CP. 
Study design: A total of 142 children and adolescents with CP, aged 6 to 18 years, were assigned to groups based 
on the different treatments they had received for drooling: G1—anticholinergic drugs (n = 18), G2—botulinum 
toxin injection (n = 16), G3—salivary glands surgery (n = 16), G4—no treatment (n = 42), and G5—non-drooling 
subjects (n = 50). All participants were evaluated on the Simplified Oral Hygiene Index, and for the prevalence 
of dental caries (decayed, missing, and filled teeth index and white spot lesions). Unstimulated whole saliva was 
collected, and salivary flow rate and osmolality were measured. Chi-square, ANOVA and Poisson regression were 
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Introduction
Cerebral palsy (CP) describes a prevalent, clinically 
important, and identifiable medical condition with non-
progressive permanent neuromotor disorders, caused 
by damage to the immature or developing brain, with 
consequent activity limitations regarding movement 
and posture (1). In CP, motor function impairments 
are frequently accompanied by disturbances of cogni-
tion and behavior, and in later life, by the development 
of musculoskeletal problems, including impairment of 
oral motor and speech functions (1). Neuromuscular im-
pairment makes individuals with CP prone to drooling 
(2). 
Saliva, responsible for mechanical cleaning and protec-
tive functions, is essential to the maintenance of oral 
health. Salivary flow rate (SFR) and its buffering action 
play a critical role in maintaining the pH of saliva (3). 
Low SFR values and higher osmolality (SO) values are 
correlated with an increased prevalence of dental caries 
in individuals with CP (4). Drooling, or sialorrhea, is 
the involuntary loss of saliva and its components from 
the mouth; it is considered a pathological condition if 
persistent after the age of 4 years (5). For individuals 
with CP, major predisposing factors for drooling in-
clude absence of cervical motor control, alterations in 
swallowing and speech (dysarthria/dyspraxia), dyspha-
gia, anterior open bite, nasal obstruction, and intraoral 
sensitivity disorder (6,7,8). The prevalence of drooling 
in CP varies from 10% (6), 40% (5), 48.7% (7), 58% (8) 
to 60.3% (9), and negatively affects the social, psycho-
logical, and physical health of these patients (10).
Numerous treatment modalities for drooling have been 
proposed by medical teams. The first option presented 
is usually oral motor therapy to improve lip closure, 
swallowing, tongue control, cervical motor control, and 
oral sensation (11). This therapeutic approach is unique 
in that it treats the etiology of drooling (12). The sec-
ond approach, the use of anticholinergic drugs, aims to 
reduce salivary volume without affecting swallowing 
function. In this context, muscarinic cholinergic recep-
tor blockers are used, such as scopolamine and atro-
pine (13). The third approach is application of botuli-
num toxin to the parotid and/or submandibular salivary 
calculated. Prevalence ratios and their respective 95 % confidence intervals were obtained. The significance level 
was fixed at 5%.
Results: No differences were found in the decayed, missing, and filled teeth index (p = 0.128) and Simplified Oral 
Hygiene Index (p = 0.674) among the different groups. G3 presented significantly higher percentages of WSL (p < 
0.001), lower values of salivary flow rate (p < 0.001), and higher values of osmolality (p < 0.001). The white spot le-
sion prevalence ratio was higher only for G3 (Prevalence ratio = 14.36; IC 95% = 4.64-44.40; p < 0.001).
Conclusions: Children and adolescents with CP who had received surgical treatment for drooling exhibited higher 
number of white spot lesions because of the reduced salivary flow rate and higher salivary osmolality.
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glands, under ultrasound guidance (14). The transient 
effect of reduction of saliva secretion and drooling is 
due to inhibition of the discharge of acetylcholine from 
cholinergic nerve terminals (14). A fourth approach, the 
surgical treatment modality, is elected when drooling 
persists after at least six months of conservative therapy 
in patients with cognitive deficits and children over 6 
years of age, when maturation of oral motor function is 
expected to occur. The best results occur when bilateral 
submandibular gland excision is performed with parotid 
duct ligation, reducing pneumonia aspiration (15).
Although the literature regarding drooling in individu-
als with CP and its therapies is extensive, only one study 
described the dental health of children with cerebral 
palsy following sialodochoplasty (16) and another, the 
use of intraglandular onabotulinum toxin A injection in 
these patients (17). Moreover, the development of white 
spot lesions (WSL) in individuals with CP, who have 
undergone different treatments for drooling, has not 
been investigated. 
Thus, the purpose of this study was to compare the effects 
of pharmacological therapy, botulinum toxin injection, 
and salivary gland surgery on salivary parameters and car-
ies risk in children and adolescents with CP. It was hypoth-
esized that individuals with CP who underwent bilateral 
removal of the submandibular glands with parotid duct 
ligation would present higher risk for dental caries (WSL) 
due to the reduction in SFR and increase in SO. 
Material and Methods 
-Ethical statement
This study was reviewed and approved by the local Hu-
man Research Ethics Committee (Plataforma Brazil 
# 1.655.830). Written informed consent was obtained 
from the guardians of each child or adolescent after 
they were informed about the study.
-Study design
An epidemiological cross-sectional study was per-
formed with children and adolescents with CP who 
were referred to a specialized physical rehabilitation 
center in São Paulo, Brazil.
-Participants
Two hundred and twenty-two children and adolescents 
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with a medical diagnosis of CP composed the conve-
nience sample in this study. Data were collected be-
tween February and October 2016.
Inclusion criteria were a medical diagnosis of CP; aged 
6–18 years; both genders; presence or absence of drool-
ing; submitted or unsubmitted to different modalities of 
drooling treatments. Participants using anticholinergic 
drugs to control drooling were required to have taken 
the medicine without interruption for at least one month 
prior to clinical examination. For the botulinum toxin 
group, the injections in submandibular and parotid 
glands were required to have been applied within three 
months prior to the dental clinical evaluation. Partici-
pants who underwent salivary gland surgery must have 
done so in 2015 and followed up with an otolaryngolo-
gist at least twice during the last six months, with an 
evaluation of surgical success. Participants who were 
G-tube fed, and those who exhibited uncooperative be-
havior during saliva collection and clinical oral exami-
nation were excluded.
According to the inclusion/exclusion criteria, the final 
sample for this study was composed of 142 subjects with 
CP, who were assigned to one of five groups depending 
on the treatment they had received for drooling or not: 
G1—drooling CP subjects who received anticholinergic 
drugs (n = 18), G2—drooling CP subjects who received 
botulinum toxin injection (n = 16), G3—drooling CP 
subjects who received surgical treatment (n = 16) G4—
drooling CP subjects who received no treatment (n = 42; 
positive control), and G5—non-drooling CP subjects (n 
= 50; negative control).
The drooling treatment proposed by the medical team 
of the rehabilitation center obeyed a stepwise approach 
to the management of drooling, i.e., pharmacotherapy, 
botulinum toxin, and surgery (18).
All children or adolescents who participated in the study 
received the same preventive protocol (biofilm control, 
professional prophylaxis, and fluoride therapy) and den-
tal treatment as needed, before the drooling treatment. 
Data regarding gender, age, medical diagnosis of CP 
according to the type of movement disorder (spastic or 
dyskinetic), and clinical pattern of involvement (tetra-
paresis, diparesis, or hemiparesis) were collected from 
their medical records.
-Clinical Evaluation
Oral Hygiene Index (OHI-S)
All evaluations were performed in a dental office un-
der appropriated light-reflector illumination in a dental 
chair, by a single examiner. Six teeth (four posterior 
and two anterior) were assessed and scored for each in-
dividual according to the Simplified Oral Hygiene In-
dex (OHI-S) (19). For the posterior teeth, the first fully 
erupted tooth distal to the second premolar or primary 
molar was examined in each quadrant. For maxillary 
molars, the buccal surfaces were scored, and for man-
dibular molars, the lingual surfaces were scored. For 
anterior teeth, the labial surfaces of the maxillary right 
and mandibular left central incisors were scored. The 
OHI-S is a combination of visible plaque and dental cal-
culus.
Dental caries assessment 
A single calibrated examiner (weighted kappa = 0.89) 
performed the clinical examination with the help of an 
assistant to record data.
Before dental assessment, professional prophylaxis 
was performed on each patient. A clinical examination 
was performed with the aid of a light reflector, air/wa-
ter spray, dental mirror, and WHO probe, according to 
World Health Organization criteria (20). Prevalence of 
dental caries was recorded according to the decayed, 
missing, and filled teeth index (dmf-t and DMF-T indi-
ces for primary and permanent dentition, respectively). 
In children with mixed dentition, dmf-t and DMF-T 
were recorded together. No radiographic examination 
was performed.
The presence of WSL was recorded according to In-
ternational Caries Detection and Assessment System 
(ICDAS) criteria (21). The presence of distinct visual 
change in enamel was recorded as ICDAS code 2 (tooth 
must be viewed wet).
Saliva collection and assessment 
Unstimulated whole saliva was collected during the 
same period (between 8:00 and 10:00 a.m.), at least 
one hour after a meal, using one absorbent cotton roll 
(Salivette®, Sarstedt, Nümbrecht, Germany) under the 
tongue, for exactly five minutes, as previously described 
by our research group (22). Saliva samples were imme-
diately frozen on dry ice, transported to the laboratory, 
and stored at -80°C. Before SFR and SO measurements 
were taken, samples were centrifuged at 5000 rpm for 
5 minutes at 4°C (Hettich Centrifuge, model Universal 
320R, Tuttlingen, Germany). SFR was calculated as 
ml/mim and SO was measured using a freezing point 
depression osmometer (Model Vapro Vapor Pressure 
Osmometer 5600, New Instrument, Washington, DC, 
USA). Prior to measurement, the osmometer was cali-
brated by the comparison method using certified stan-
dard liquids for the calibration of SO (OPTIMOLE TM 
290 and 1000 mmol/kg Osmolality Standard ELITech 
Group WESCOR). 
-Statistical analysis
Analyses of descriptive statistics were performed to 
calculate demographic data. Inferential analyses were 
performed using Chi-square and ANOVA tests. Poisson 
regression analysis was performed to identify factors 
associated with the presence of WSL. Prevalence ra-
tios (PR) and their respective 95 % confidence intervals 
were obtained. SPSS Statistical Package for the Social 
Sciences 19.0 (IBM Brazil, SP, Brazil) was used for all 
analyses, with a significance level of 5%. 
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Results
A total of 142 children and adolescents with CP were 
enrolled in the study; 63.4% were male and 36.6% were 
female. Mean (± SD) age was 9.8 (± 2.9). The follow-up 
period (from the beginning of each treatment modality 
to the clinical examination) ranged from 4.00 to 5.00 
months, with an average and standard deviation (SD) of 
4.4 ± 0.9, with no statistical differences between the five 
groups (p = 0.105, ANOVA test). 
Descriptive statistics regarding gender, age, and types 
of movement disorders are shown in Table 1. Eighteen 
participants (12.7%) had been treated using anticholin-
ergic drugs (G1), 16 (11.3%) had been treated with botu-
linum toxin injection (G2), and 16 (11.3%) had received 
surgical treatment (G3). Drooling subjects who received 
no treatment (42, 29.6%) were positive controls (G4), 
and non-drooling subjects (50, 35.1%) were considered 
to be negative controls (G5). The groups were statisti-
cally homogeneous regarding gender (p = 0.102) and 
age (p = 0.915). Considering the different types of CP 
movement disorders, the groups differed significantly 
(p < 0.001), and the negative control group (G5) showed 
the highest percentage of subjects with spastic diparesis 
(54.0%).
The power of the study for the sample was calculated as 
99.5% and 100.0%, considering the SFR and SO values 
of the groups, with alpha = 5% (OpenEpi). 
Table 2 shows mean (± SD) for DMF-T index, frequen-
cy of WSL, OHI-S, SFR, and SO for all groups. In re-













Gender - n (%) 
Male 14 (77.8) 12 (75.0) 8 (50.0) 30 (31.4) 26 (52.0) 0.102† 
Female 04 (22.2) 04 (25.0) 08 (50.0) 12 (28.6) 24 (48.0) 
Age - years 
(mean ± SD) 
9.8 ± 2.9 9.9 ± 3.1 9.1 ± 1.4 9.9 ± 3.9 9.9 ± 2.7 0.915* 
Movement disorder - n (%) 
Spasticity <0.001† 
    Tetraparesis 13 (72.2) 11 (68.8) 9 (56.2) 21 (50.0) 15 (30.0) 
    Diparesis 4 (22.2) 2 (12.5) 0 (0.0) 8 (19.0) 27 (54.0) 
    Hemiparesis 0 (0.0) 2 (12.5) 2 (12.5) 2 (4.8) 0 (0.0) 
Dyskinesia 1 (5.6) 1 (6.2) 5 (31.3) 11(26.2) 8 (16.0) 
 
Table 1. Descriptive characteristics of children and adolescents with CP who were submitted or not to different treatment modalities of drool-
ing.
G1: Drooling and pharmacological therapy
G2: Drooling and botulinum toxin injection
G3: Drooling and surgical treatment
G4: Drooling and no treatment (positive control)















DMF-T index (mean ± SD) 1.2 ± 1.8 0.9 ± 1.4 2.4 ± 2.8 1.2 ± 1.9 1.0 ± 1.5 0.366 
White Spot Lesions - n (%) 
Presence 4 (22.2) 3 (18.7) 13 (81.2) 7 (16.7) 3 (6.0) <0.001ɬ 
Absence 14 (77.8) 13 (81.3) 3 (18.8) 35(83.3) 47 (94.0) 
OHI-S 2.47±0.54 2.22±0.61 2.28±0.66 2.39±0.54 2.36±0.57 0.674 
Salivary Flow Rate 
mL/min 
 (mean ± SD) 
0.3 ± 0.2A 0.2 ± 0.1B 0.1 ± 0.1C 0.3 ± 0.1A 0.4 ± 0.1A <0.001* 
Salivary Osmolality 
mOsm/kgH2O (mean ± SD) 
75.5 ± 16.0 A 92.9 ± 12.8B 151.2 ± 25.14C 72.2 ± 25.0 A 71.4 ± 13.5 A <0.001* 
 
Table 2. Mean values and standard deviation (±SD) for DMF-T index, salivary flow rate, salivary osmolality and frequency of white spot lesion 
(WSL) of children and adolescents with CP who were submitted or not to different treatment modalities of drooling.
G1: Drooling and pharmacological therapy
G2: Drooling and botulinum toxin injection
G3: Drooling and surgical treatment
G4: Drooling and no treatment (positive control)
G5: Non-drooling (negative control)
*Different superscript capital letters in the same line indicates statistically significant differences by 
 ANOVA and post hoc Tukey tests (p<0.05)
ɬChi-square test
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0.674) no significant difference were reported among 
the groups. Children and adolescents that underwent 
surgical treatment (G3) presented significantly higher 
percentages of WSL (p < 0.001), lower mean values for 
SFR (p < 0.001), and higher values of SO (p < 0.001) 
than the other treatments modalities and control groups. 
Table 3 shows the results of the Poisson regression 
analysis for the presence of WSL according to charac-
teristics of children and adolescents with CP who did 
or did not undergo different treatment modalities for 
drooling. Based on the adjusted model, the prevalence 
ratio for WSL was observed to be higher for all treat-
ment modalities, and there was statistically significant 
for the surgical treatment group alone (prevalence ratio 
= 14.36; IC 95% = 4.64-44.40; p < 0.001).
 Univariate analysis Multivariate analysis* 
Variables PR Non-adjusted 
(95% CI) 
P-value PR Adjusted 
(95% CI) 
P-value 
Sex     
 Female 1.32 (0.70-2.50) 0.388 - - 
 Male 1  - - 
Age 1.02 (0.92-1.12) 0.715 - - 
Group     
 G1 3.70 (0.92-14.97) 0.066 3.88 (0.93-16.16) 0.062 
 G2 3.12 (0.70-13.98) 0.136 3.24 (0.71-14.74) 0.129 
 G3 13.54 (4.41-41.59) <0.001 14.36 (4.64-44.40) <0.001 
 G4 2.78 (0.77-10.08) 0.120 2.90 (0.77-10.86) 0.114 
 G5 1  1  
 
Table 3. Poisson regression analysis for the presence of white spot lesion (WSL) according to characteristics of children and adoles-
cents with CP who were submitted or not to different treatment modalities of drooling.
G1: Drooling and pharmacological therapy
G2: Drooling and botulinum toxin injection
G3: Drooling and surgical treatment
G4: Drooling and no treatment (positive control)
G5: Non-drooling (negative control)
PR = prevalence ratio
95% CI = 95% confidence interval
* Model adjusted for sex and age.
Discussion 
The presence of drooling requires treatment, and the 
literature describes different therapeutic modalities. To 
our knowledge, this is the first study to evaluate and 
compare the effects of pharmacological therapy, botu-
linum toxin injections, and salivary gland surgery in 
children and adolescents with CP regarding caries risk, 
considering initial caries lesions (ICDAS code 2) and 
salivary parameters.
The localization and extent of neuromotor disorder are 
responsible for the great variability of motor impairment 
and functional independence of individuals with CP (1). 
Spastic CP, characterized by increased muscle tone and 
presence of spasticity, is the most common movement 
disorder among CP individuals, with a prevalence of 
70-80% (1). In the present study, most of the partici-
pants (81.7%) presented spasticity; 48.6% of all partici-
pants presented with tetraparesis—the highest level of 
motor impairment—with all limbs compromised, dif-
ficulty with cervical motor control, delayed maturation 
of oral motor function, alterations in swallowing and 
speech, anterior open bite, nasal obstruction, intraoral 
sensitivity disorder (2, 5) and moderate to severe drool-
ing, as observed in this study. About 28.9% participants 
presented with diparesis, with upper limb motor control 
and usually with preserved oral motor functions, which 
reduced the prevalence of drooling. Consistent with the 
literature, a higher prevalence of males with CP (63.4%) 
was observed, but the reasons for which remain unclear 
(22). 
It should be emphasized that the presence of dysphagia 
and increased saliva production may increase the risk 
for aspiration pneumonia, and consequently, pulmonary 
complications, which are the main indications for treat-
ment of drooling in individuals with CP (2). The con-
stant presence of wet clothing, perioral dermatitis, and 
infections require treatment (10,23). Drooling is also 
distressing for patients with CP, with negative conse-
quences on their social, emotional, and psychological 
health. Once treated, patients present improvement in 
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self-esteem and social interactions, and reduction in 
daily care needs (23). The high prevalence of drooling 
in individuals with CP motivates clinicians to offer ef-
fective and individualized treatment choices to improve 
health and quality of life (11). However, limitations ex-
ist for all treatments for drooling, and except for surgi-
cal treatment, they are all temporary. Furthermore, all 
treatment modalities target the consequences of drool-
ing, reducing salivary volume (24), but fail to address 
the predisposing factors or causes (12).
Regarding dental caries, significant limitations should 
be discussed when using the DMF-T index proposed by 
World Health Organization (20) in oral epidemiological 
surveys. This index does not provide information re-
lated to non-cavitated caries lesions (25). If assessed in 
their early stages, caries lesions can be arrested through 
preventive programs, which can also lower the costs re-
lated to restorative treatment (26). In the present inves-
tigation, the DMF-T index was used in association with 
the ICDAS criteria (code 2) to evaluate incipient caries 
lesions in this population.
It should be noticed that the DMF-T index (total num-
ber of teeth that are decayed, missing or filled) did not 
statistically differ among the groups.  This fact could be 
explained by the inclusion criteria of the participants, 
which should have been submitted recently to different 
treatment modalities for drooling (within a maximum 
period of 6 months). Thus, the primary impact of the 
treatments is related to the development of white spot 
lesions and not caries lesions with cavitation, which 
tends to progress slowly.
As previously described, individuals with CP present 
lower SFR associated with higher SO (27) values, which 
are potential risk factors for dental caries (4) and gin-
givitis (28). In this context, the surgical procedure was 
the most harmful treatment modality observed in this 
study, resulting in a higher prevalence of WSL com-
pared to the other treatments. The homogeneity among 
the groups, regarding oral hygiene (as measured by the 
OHI-S), allows us to state that the difference in WSL 
observed in G3 is due to the reduction of SFR and in-
crease of SO. 
Although there was no pairing in relation to the num-
ber of children and adolescents submitted to different 
treatment modalities in relation to gender and age, the 
adjusted multivariate regression analysis showed no sta-
tistical difference in relation to the presence of active 
WSL among children and adolescents with CP. 
One significant problem experienced by participants 
who underwent treatment for drooling was the appear-
ance of active WSL. This condition requires immediate 
non-invasive treatment by application of fluoride var-
nish or occlusal sealants with fluoride-releasing mate-
rial, such as the latest generation of glass-ionomer ce-
ments. If patients’ initial lesions are not controlled, they 
may progress toward cavitation, painful sensation, dif-
ficulty in chewing, and the need for functional aesthetic 
rehabilitation.
According to the data of the last Brazilian Oral Health 
Survey (SB Brazil 2010), healthy children living in São 
Paulo, Brazil, present dental caries experience of 1.99 
at the age of 5 years and 1.41 at the age of 12 years (29). 
Considering that the mean age presented by the partici-
pants of the present investigation was approximately 10 
years old, and individuals with CP present a significant 
delay in tooth eruption, it can be inferred that the dental 
caries experience was similar in CP and in healthy chil-
dren and adolescents.
Limitations of this study include the design (cross-sec-
tional), the convenience sample, and the location: a ref-
erence rehabilitation center. Nevertheless, regarding the 
treatment modalities discussed in this study, surgical 
treatment demonstrated to be responsible for the caries 
risk of participants, due to the reduced SFR, increased 
SO values, and number of WSL. In this context, it is es-
sential to include dental surgeons in multi-disciplinary 
medical teams (18, 30), in order to prevent and treat the 
early signs of damage caused by treatments for drool-
ing and to maintain individuals’ follow-ups to promote 
oral health. Moreover, caregivers of CP individuals 
should be informed about the oral health consequences 
of drooling treatment, such as difficulty in chewing and 
swallowing, thick saliva, and halitosis.
Conclusions
Children and adolescents with cerebral palsy who have 
undergone surgical treatment for drooling exhibited 
higher number of white spot lesions compared to the 
other treatments, due to lower SFR rate, higher SO val-
ues and presence of WSL.
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